Get the Stockscreener App
2.38
7.21%
0.16
Grace Therapeutics Inc stock is traded at $2.38, with a volume of 274.85K.
It is up +7.21% in the last 24 hours and up +9.68% over the past month.
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.
See More
Previous Close:
$2.22
Open:
$2.22
24h Volume:
274.85K
Relative Volume:
0.38
Market Cap:
$38.73M
Revenue:
-
Net Income/Loss:
$-5.98M
P/E Ratio:
-6.6056
EPS:
-0.3603
Net Cash Flow:
$-9.83M
1W Performance:
+3.48%
1M Performance:
+9.68%
6M Performance:
-28.96%
1Y Performance:
-22.48%
1-Day Range:
$2.2145
$2.38
1-Week Range:
$2.13
$2.38
52-Week Range:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.38 | 38.73M | 0 | -5.98M | -9.83M | -0.3603 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104 - GuruFocus
Grace Therapeutics narrows FY26 net loss to $7.8 million - scanx.trade
Grace Therapeutics, Inc (GRCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grace Therapeutics, Inc (GRCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Grace Therapeutics, Inc (GRCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Grace Therapeutics Reports 2026 Financial Results, Advances GTx-104 NDA Resubmission for aSAH Treatment After FDA CRL – STRIVE-ON Phase 3 Data Highlights and IP Expansion – Minichart - Minichart
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress - TipRanks
Grace Therapeutics (NASDAQ: GRCE) updates GTx-104 data, FDA CRL response and cash - Stock Titan
Grace Therapeut reports $7.8M net loss, $17.0M cash at FY2026 year-end - TradingView
GRCE: Net loss narrowed as GTx-104 advanced toward FDA resubmission, with strong trial results and IP gains - TradingView
Grace Therapeutics (NASDAQ: GRCE) narrows 2026 loss and details FDA path for GTx-104 - Stock Titan
Grace Therapeutics sets FDA meeting after GTx-104 CRL - Stock Titan
Grace: Fiscal Q4 Earnings Snapshot - marketscreener.com
Grace Therapeutics FY 2026: Net loss $(7.8)M, EPS $(0.47) — 10-K Summary - TradingView
GRCE: Net loss improved to $7.8M as R&D spending fell, but FDA CRL delays GTx-104 approval - TradingView
Grace Therapeutics (Nasdaq: GRCE) faces GTx-104 FDA CRL and writes down two pipeline drugs - Stock Titan
Grace Therapeutics reports 2026 fiscal results - grafa.com
Grace Therapeutics, Inc (GRCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Grace Therapeutics, Inc (GRCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GRCE Q4'25 Earnings: revenue estimate is 0 USD - TradingView
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor ConfidenceEPS Estimate Trend - newsline.com
GRCE Q1 2026 Earnings: EPS Beats Estimates by Wide Margin Amid No Reported RevenueEarnings Yield Spread - newsline.com
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Should I Buy - Intellectia AI
GRACE THERAPEUTICS INC (GRCE) Stock Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Lelezard
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-07 | Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
Grace Therapeutics VP of Clinical Operations Departs Role - The Globe and Mail
Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12‑month consulting agreement - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect | NDAQ:GRCE | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Grace Therapeutics, Inc. (GRCE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. - GlobeNewswire
GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2026-06-03 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Investors to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
GRCE Technical Analysis | Trend, Signals & Chart Patterns | GRACE THERAPEUTICS INC (NASDAQ:GRCE) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Reach Out - ACCESS Newswire
Grace Therapeutics: A Manufacturing Setback Priced As A Death Sentence (NASDAQ:GRCE) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therape - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect - ACCESS Newswire
2026-05-31 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Stockholders to Connect | NDAQ:GRCE | Press Release - Stockhouse
Grace Therapeutics (GRCE) Jumps 5.76%: Testing Resistance at $2.7 After Support HoldPullback Trade - newsline.com
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz - The National Law Review
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):